App-Quantinova.ai

Anti CD19 CAR-T Cell Therapy Can Clear Minimal Residual Disease in Bone Marrow of Patients with Relapsed or Refractory B Cell Non-Hodgkin's Lymphomas

Armaan Dhaliwal - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

N/A

Posterior Reversible Encephalopathy Syndrome: A Rare Side Effect of Nivolumab

Muhammad Shan Ul Abedin - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Solid malignancies

Fluorouracil

Lambert Eaton Myasthenic Syndrome (LEMS) Secondary to Atezolizumab in a Patient with Squamous Cell Carcinoma of the Lung

Muhammad Shan Ul Abedin - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

Pyridostigmine Bromide

Early Use of Antibiotics and Unfavorable Results after Allogeneic Hematopoietic Stem Cell Transplantation, a Competing Risk Analysis in a Cohort of 274 Patients

Pamela Velásquez-Salazar - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

Cyclophosphamide

Influence of Conditioning Regimen Intensity on Outcomes Post-Allogeneic Transplantation for AML in Complete Morphological Remission

Tommy Alfaro - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

fludarabine tablet

A Retrospective Cohort Study of Donor Cell Leukemia

Brittany Salter - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Novel First-in-Class Drug ONC201 As a Post-Transplant Maintenance for AML and MDS: A Phase I Trial in Progress

Vijaya Raj Bhatt - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

Prednisone

Time-Series Reconstruction of CBC Profile of Pediatric Cancer Patients for Two Years after Hematopoietic Stem Cell Transplantation Using Language Programming

Seok-Jin Lee - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

Cyclosporine eent

Single Cell Gene Expression Predicts Plasma Cell Leukemia Patient Response to Daratumumab

Jonathan Adam Scolnick - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

daratumumab Intravenous

A Retrospective Analysis of Thromboprophylaxis in Hospitalized Patients with Cancer

Alex Dipierdomenico - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

N/A

Avoiding Daratumumab Interference with Blood Typing

Charity A Huang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

daratumumab Intravenous

Improving Quality of Life and Treatment Adherence in Multiple Myeloma Patients Using Education Strategies Based on Digital and Spaced Learning

Juan Francisco Francisco Guio OROS - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Peripheral Nervous System

Solid malignancies

N/A

Development of a Virtual Platform to Combat Global Inequity in Oncological Education

Yan Leyfman - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Solid malignancies

N/A

Genetics of Multiple Myeloma in Latin America

Paola E. Leone - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Solid malignancies

N/A

Patients Experience with Telemedicine during COVID-19 Pandemic in a Tertiary Cancer Center in Qatar

Israa Elhakeem - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Solid malignancies

N/A

Age of Packed Red Blood Cells Transfused to Patients with Acute Leukemia: A Descriptive Analysis

Omer H Jamy - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

N/A

Development of the Autonomous Nurse Practitioner Role in an Outpatient Malignant Hematology Unit a Twenty-Year Odyssey

Suzanne Rowland - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

N/A

Assessing Immune Response to 3rd Dose of COVID-19 Vaccine Series in Patients Undergoing Cancer Treatment at University Medical Center- New Orleans

Anh Q. Nguyen - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Solid malignancies

N/A

Retrospective Data Collection Study: Hematologic Toxicities with Immunotherapy in Cancer Patients at the Allan Blair Cancer Centre

Amani Khan - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

Anti-CTLA4

Closing the Gap: Implementation of a Novel Interactive Virtual Tumor Board to Improve Expert Knowledge Sharing in Malignant Hematology

Jordan Ciuro - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts